155 related articles for article (PubMed ID: 26024383)
1. Peptide 19-2.5 inhibits heparan sulfate-triggered inflammation in murine cardiomyocytes stimulated with human sepsis serum.
Martin L; Schmitz S; De Santis R; Doemming S; Haase H; Hoeger J; Heinbockel L; Brandenburg K; Marx G; Schuerholz T
PLoS One; 2015; 10(5):e0127584. PubMed ID: 26024383
[TBL] [Abstract][Full Text] [Related]
2. Soluble Heparan Sulfate in Serum of Septic Shock Patients Induces Mitochondrial Dysfunction in Murine Cardiomyocytes.
Martin L; Peters C; Schmitz S; Moellmann J; Martincuks A; Heussen N; Lehrke M; Müller-Newen G; Marx G; Schuerholz T
Shock; 2015 Dec; 44(6):569-77. PubMed ID: 26529654
[TBL] [Abstract][Full Text] [Related]
3. The Synthetic Antimicrobial Peptide 19-2.5 Interacts with Heparanase and Heparan Sulfate in Murine and Human Sepsis.
Martin L; De Santis R; Koczera P; Simons N; Haase H; Heinbockel L; Brandenburg K; Marx G; Schuerholz T
PLoS One; 2015; 10(11):e0143583. PubMed ID: 26600070
[TBL] [Abstract][Full Text] [Related]
4. The synthetic antimicrobial peptide 19-2.5 attenuates mitochondrial dysfunction in cardiomyocytes stimulated with human sepsis serum.
Martin L; Peters C; Heinbockel L; Moellmann J; Martincuks A; Brandenburg K; Lehrke M; Müller-Newen G; Marx G; Schuerholz T
Innate Immun; 2016 Nov; 22(8):612-619. PubMed ID: 27624711
[TBL] [Abstract][Full Text] [Related]
5. Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-
Zechendorf E; Vaßen P; Zhang J; Hallawa A; Martincuks A; Krenkel O; Müller-Newen G; Schuerholz T; Simon TP; Marx G; Ascheid G; Schmeink A; Dartmann G; Thiemermann C; Martin L
Front Immunol; 2018; 9():393. PubMed ID: 29616016
[TBL] [Abstract][Full Text] [Related]
6. Targeting the "sweet spot" in septic shock - A perspective on the endothelial glycocalyx regulating proteins Heparanase-1 and -2.
Pape T; Hunkemöller AM; Kümpers P; Haller H; David S; Stahl K
Matrix Biol Plus; 2021 Dec; 12():100095. PubMed ID: 34917926
[TBL] [Abstract][Full Text] [Related]
7. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads.
Gruda MC; Ruggeberg KG; O'Sullivan P; Guliashvili T; Scheirer AR; Golobish TD; Capponi VJ; Chan PP
PLoS One; 2018; 13(1):e0191676. PubMed ID: 29370247
[TBL] [Abstract][Full Text] [Related]
8. Peptides with dual mode of action: Killing bacteria and preventing endotoxin-induced sepsis.
Brandenburg K; Heinbockel L; Correa W; Lohner K
Biochim Biophys Acta; 2016 May; 1858(5):971-9. PubMed ID: 26801369
[TBL] [Abstract][Full Text] [Related]
9. PAMPs and DAMPs in Sepsis: A Review of Their Molecular Features and Potential Clinical Implications.
Cicchinelli S; Pignataro G; Gemma S; Piccioni A; Picozzi D; Ojetti V; Franceschi F; Candelli M
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256033
[TBL] [Abstract][Full Text] [Related]
10. An antimicrobial helix A-derived peptide of heparin cofactor II blocks endotoxin responses in vivo.
Papareddy P; Kalle M; Singh S; Mörgelin M; Schmidtchen A; Malmsten M
Biochim Biophys Acta; 2014 May; 1838(5):1225-34. PubMed ID: 24522010
[TBL] [Abstract][Full Text] [Related]
11. Sepsis-induced myocardial dysfunction: pathophysiology and management.
Kakihana Y; Ito T; Nakahara M; Yamaguchi K; Yasuda T
J Intensive Care; 2016; 4():22. PubMed ID: 27011791
[TBL] [Abstract][Full Text] [Related]
12. Sequential N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin Measurements During Albumin Replacement in Patients With Severe Sepsis or Septic Shock.
Masson S; Caironi P; Fanizza C; Carrer S; Caricato A; Fassini P; Vago T; Romero M; Tognoni G; Gattinoni L; Latini R;
Crit Care Med; 2016 Apr; 44(4):707-16. PubMed ID: 26571184
[TBL] [Abstract][Full Text] [Related]
13. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure.
Rudiger A; Gasser S; Fischler M; Hornemann T; von Eckardstein A; Maggiorini M
Crit Care Med; 2006 Aug; 34(8):2140-4. PubMed ID: 16763507
[TBL] [Abstract][Full Text] [Related]
14. Circulating glycosaminoglycan species in septic shock.
Nelson A; Berkestedt I; Bodelsson M
Acta Anaesthesiol Scand; 2014 Jan; 58(1):36-43. PubMed ID: 24341693
[TBL] [Abstract][Full Text] [Related]
15. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis.
Claus RA; Otto GP; Deigner HP; Bauer M
Curr Mol Med; 2010 Mar; 10(2):227-35. PubMed ID: 20196725
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide and hemorrhagic shock cause systemic inflammation by different mechanisms.
van Wessem KJ; Heeres M; Leliefeld PH; Koenderman L; Leenen LP
J Trauma Acute Care Surg; 2013 Jan; 74(1):37-43; discussion 43-4. PubMed ID: 23271075
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer, immunoregulatory, and antimicrobial activities of the frog skin host-defense peptides pseudhymenochirin-1Pb and pseudhymenochirin-2Pa.
Mechkarska M; Attoub S; Sulaiman S; Pantic J; Lukic ML; Conlon JM
Regul Pept; 2014 Nov; 194-195():69-76. PubMed ID: 25447194
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties.
Harris N; Kogan FY; Il'kova G; Juhas S; Lahmy O; Gregor YI; Koppel J; Zhuk R; Gregor P
Biochim Biophys Acta; 2014 Jan; 1840(1):245-54. PubMed ID: 24060749
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial peptide P18 inhibits inflammatory responses by LPS- but not by IFN-gamma-stimulated macrophages.
Nan YH; Jeon YJ; Park IS; Shin SY
Biotechnol Lett; 2008 Jul; 30(7):1183-7. PubMed ID: 18327539
[TBL] [Abstract][Full Text] [Related]
20. Midkine, a multifunctional cytokine, in patients with severe sepsis and septic shock: a pilot study.
Krzystek-Korpacka M; Mierzchala M; Neubauer K; Durek G; Gamian A
Shock; 2011 May; 35(5):471-7. PubMed ID: 21192283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
